Head to Head Comparison: Allarity Therapeutics (NASDAQ:ALLR) & Synlogic (NASDAQ:SYBX)

Allarity Therapeutics (NASDAQ:ALLR) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Allarity Therapeutics and Synlogic, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1	0	1	0	2.00
Synlogic	0	0	0	0	0.00

Allarity Therapeutics presently has a consensus price target of $10.25, indicating a potential upside of 935.35%. Given Allarity Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Allarity Therapeutics is more favorable than Synlogic.

Profitability

This table compares Allarity Therapeutics and Synlogic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
Synlogic	N/A	-26.47%	-18.00%

Volatility & Risk

Allarity Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Valuation & Earnings

This table compares Allarity Therapeutics and Synlogic”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$345,000.00	45.66	-$11.23 million	($0.78)	-1.27
Synlogic	$8,000.00	1,684.24	-$23.36 million	($0.06)	-18.33

Allarity Therapeutics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Synlogic beats Allarity Therapeutics on 7 of the 13 factors compared between the two stocks.

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

About Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.